DXCM vs ZBH — Key Metrics
| Metric | DXCM (DEXCOM INC) | ZBH (ZIMMER BIOMET HOLDINGS INC) |
|---|---|---|
| Price | 82.52 | 103.32 |
| Market Cap | 30.78 Billion | 19.55 Billion |
| P/E (TTM) | 31.86 | 26.03 |
| P/B (Quarterly) | 11.758 | 1.639 |
| P/S (TTM) | 6.03 | 2.28 |
| Net Profit Margin (TTM) | 19.4 | 9.0 |
| Gross Margin (TTM) | 63.4 | 69.7 |
| ROE (TTM) | 36.5 | 6.1 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Outperform
Underperform
Recommendation Summary
Stock DXCM is projected to outperform the market, stock ZBH is projected to underperform the market. Upfront Recommendation: DXCM.
Financial Metrics
| DXCM | Metrics | ZBH |
|---|---|---|
| $82.52 | Price | $103.32 |
| — | Market Capitalization | — |
| 31.86 | Price to Earnings Ratio | 26.03 |
| 6.03 | Price to Sales | 2.28 |
| 28.02 | Price to FCF Ratio | 15.1 |
| 9.51 | Price to Gross Profit | 3.27 |
| 50.61 | Price to R&D | 45.18 |
| 7.86 | Price to Current Assets | 3.81 |
DXCM vs ZBH at a glance
Dexcom INC (DXCM) and Zimmer Biomet Holdings INC (ZBH) are both Medical Devices companies in the Healthcare sector. DXCM is the larger, at $30.8 billion in market value against $19.6 billion for ZBH, about 1.6 times the size.
On trailing-twelve-month figures, DXCM trades at 31.9 times trailing earnings and ZBH at 26.0; net profit margins are 19.4% and 9.0%.
The Upfront Investment model currently rates DXCM Outperform and ZBH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.